Nexus BioPharma signs deal with TransChem for kinase inhibition technology
Nexus BioPharma has signed an agreement to license TransChem's transition state chemistry technology for kinase inhibition.
Kinases are enzymes that regulate essential cellular…
Read More...
Read More...
